Uncertainty Surrounds Lyrica Patent Extension

Whether Pfizer will receive a patent extension for Lyrica, a drug often prescribed to injured workers, remains to be seen, according to a recent SEC filing by the company. “We lost or expect to lose exclusivity for various other products in various markets over the next few years, including, among others, the expiration of the basic product patent for Lyrica in the U.S. in December 2018," Pfizer said in a Form 10-Q dated Aug. 9 and filed with the Securities and Exchange Commission. "Pfizer is currently pursuing a six-month patent-term extension for pediatric exc...